Comparing the subjective, psychomotor and physiological effects of intravenous butorphanol and morphine in healthy volunteers

JP Zacny, JL Lichtor, P Thapar, DW Coalson, D Flemming and WK Thompson

Department of Anesthesia and Critical Care, Pritzker School of Medicine, University of Chicago, Illinois.

The purposes of this study were to characterize the subjective, psychomotor and physiological effects of butorphanol in healthy nondrug- abusing volunteers and to compare and contrast the effects of butorphanol to those of morphine. Into an antecubital vein, the subjects (seven men and five women), who had no history of opiate dependence, were injected with 0, 0.5, 1.0 or 2.0 mg/70 kg of butorphanol or 10 mg/70 kg of morphine; a randomized, double-blind, crossover design was used. The subjective effects of butorphanol included increased scores on the Pentobarbital-Chlorpromazine-Alcohol Group scale and Lysergic Acid Diethylamide scale of the Addiction Research Center inventory; increased visual analog scale ratings of "sedated," "coasting or spaced out" and "difficulty concentrating;" increased adjective checklist ratings of "sweating," "skin itchy" and "sleepy;" and increased "feel drug effect" and drug-liking ratings. Morphine had some subjective effects of a magnitude similar to those of an equianalgesic dose of butorphanol (2 mg) (e.g., "strength of drug effect," "sedated," "heavy or sluggish feeling" and "high"). However, other effects of morphine were lesser in magnitude (e.g., "coasting or spaced out," "drunken" and "lightheaded") than those of butorphanol. Also, morphine did not affect a number of ratings that were affected by butorphanol (e.g., "confused," "dreamy," "stimulated," "difficulty concentrating," "floating" or "sweating"). The psychomotor impairing effects of butorphanol, as measured by the Maddox Wing test, an eye- hand coordination test, and the Digit Symbol Substitution Test, were dose related; in contrast, morphine had no effect on psychomotor functioning. Both butorphanol and morphine induced miosis.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 270, Issue 2, pp. 579-588, 08/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				P. McNamara Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care Palliative Medicine, July 1, 2002; 16(5): 425 - 434. [Abstract] [PDF]

				L. A. Marsch, W. K. Bickel, G. J. Badger, J. P. Rathmell, M. D. B. Swedberg, B. Jonzon, and C. Norsten-Hoog Effects of Infusion Rate of Intravenously Administered Morphine on Physiological, Psychomotor, and Self-Reported Measures in Humans J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1056 - 1065. [Abstract] [Full Text] [PDF]

				D. J. Walker and J. P. Zacny Subjective, Psychomotor, and Physiological Effects of Cumulative Doses of Opioid µ Agonists in Healthy Volunteers J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1454 - 1464. [Abstract] [Full Text]

				J. P. Zacny, J. L. Hill, M. L. Black, and P. Sadeghi Comparing the Subjective, Psychomotor and Physiological Effects of Intravenous Pentazocine and Morphine in Normal Volunteers J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1197 - 1207. [Abstract] [Full Text]

				S. L. Walsh, R. E. Johnson, E. J. Cone, and G. E. Bigelow Intravenous and Oral l-alpha -Acetylmethadol: Pharmacodynamics and Pharmacokinetics in Humans J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 71 - 82. [Abstract] [Full Text]

				J. P. Zacny, K. Conley, and J. Galinkin Comparing the Subjective, Psychomotor and Physiological Effects of Intravenous Buprenorphine and Morphine in Healthy Volunteers J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1187 - 1197. [Abstract] [Full Text]

				J. P. Zacny, K. Conley, and S. Marks Comparing the Subjective, Psychomotor and Physiological Effects of Intravenous Nalbuphine and Morphine in Healthy Volunteers J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1159 - 1169. [Abstract] [Full Text]